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Abstract
Background: CCAAT/enhancer binding protein-delta (C/EBP-delta) is a member of the highly conserved C/EBP
family of basic region leucine zipper transcription factors. C/EBP family members regulate cell growth and
differentiation and “loss of function” alterations in C/EBPs have been reported in a variety of human cancers. C/
EBP-delta gene expression is upregulated by G0 growth arrest, IL-6 family cytokines and endotoxin treatments. C/
EBP-delta exhibits properties of a tumor suppressor gene, including reduced expression and promoter methylation-
induced silencing in transformed cell lines and primary tumors. In addition, C/EBP-delta gene expression is
repressed by c-Myc, an oncogene that is over-expressed in a wide range of human cancers. “ChIP-chip” studies
demonstrated that C/EBP-delta functions as a transcriptional activator of target genes that function in intracellular
signal transduction, transcription, DNA binding/repair, cell cycle control, cell adhesion, and apoptosis. Despite
progress in determining the biochemical functions of C/EBP-delta, the specific cellular defects that are induced by
C/EBP-delta “loss of function” alterations are poorly understood. This study investigated the impact of C/EBP-delta
“loss of function” alterations on growth arrest, migration/invasion and differentiation in nontransformed mouse
mammary epithelial cells (MECs) and primary mouse embryo fibroblasts (MEFs).
Results: C/EBP-delta siRNA transfected MECs exhibited ~90% reduction in C/EBP-delta mRNA and protein levels. C/
EBP-delta siRNA treatment resulted in defective growth arrest as demonstrated by persistently elevated BrdU
labeling,
3H-thymidine incorporation and cyclin D1 levels in response to growth arrest treatments. C/EBP-delta
siRNA treatment also resulted in increased migration/invasion and defective differentiation. C/EBP-delta knockout
MEFs exhibited defective growth arrest and increased proliferation/migration. Re-introduction of C/EBP-delta
expression restored the growth arrest response of C/EBP-delta knockout MEFs. Finally, deletion of the C/EBP-delta
DNA binding domain or the C/EBP-delta bZIP domain resulted in the loss of C/EBP-delta growth inhibition in
clonogenic assays.
Conclusions: This study demonstrates that C/EBP-delta functions in the regulation of critical cell fate determining
programs such as growth arrest, migration, and differentiation. These results support the tumor suppressor function
of C/EBP-delta and identify potential mechanisms in which “loss of function” alterations in C/EBP-delta could
promote cell transformation and tumorigenesis.
Background
CCAAT/enhancer binding proteins (C/EBPs) are a
highly conserved family of basic region leucine zipper
(bZip) transcription factors [1]. The C/EBP family
includes six family members: C/EBPa, C/EBPb,C / E B P g,
C/EBPδ,C / E B P ε,a n dC / E B P ζ [1,2]. C/EBP proteins
exhibit significant amino acid homology (>90%) in the
bZip (C-terminal) domain, however, the N-terminal
regions of C/EBPs are quite divergent exhibiting <20%
sequence homology [1]. C/EBPs influence cell fate by
forming homo- or heterodimers with other C/EBP
family members as well as other bZip-containing pro-
teins such as Fos, Jun and cyclic AMP response element
binding protein (CREB) [1-3]. C/EBPs also interact with
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(Rb), E2F, cyclin dependent kinase4 (CDK4) and p21 via
the C/EBP N terminal region [1-3]. C/EBP family mem-
bers, particularly C/EBPa and C/EBPδ, exhibit cell type
specific anti-proliferative activities and, as a result, have
been termed “molecular stop signs” [2,4].
C/EBPδ gene expression is highly induced in a wide
range of cell types by growth arrest treatments [2]. C/
EBPδ is induced in primary human mammary epithelial
cells and human and mouse non-transformed mammary
epithelial cell lines in response to growth arrest treat-
ments (serum and growth factor withdrawal, contact
inhibition) and IL-6 family cytokine treatment [5-8]. C/
EBPδ is also induced in human prostate cancer derived
cells (LnCAP) and in KCL22 and K562 chronic myelo-
genous leukemia (CML) cell lines in response to growth
arrest and IL-6 family treatments [9,10]. The induction
of C/EBPδ expression in response to growth arrest treat-
ments has functional consequences as ectopic C/EBPδ
expression induces growth arrest in mammary epithelial,
prostate, CML and AML derived cell lines [6,9-11]. In
addition, C/EBPδ knockout female mice exhibit
increased mammary epithelial cell proliferation and duc-
tal hyperplasia, demonstrating that reduced C/EBPδ
expression results in mammary epithelial cell growth
abnormalities in vivo [12].
C/EBPδ “loss of function” alterations have been
demonstrated in a number of human cancers. We
reported that C/EBPδ expression is reduced in 32% (18/
57) of primary human breast tumors, a finding consis-
tent with Serial Analysis of gene Expression (SAGE)
results from Polyak and coworkers [13-15]. The associa-
tion between reduced C/EBPδ expression and mammary
tumorigenesis has also been demonstrated in mammary
tumor prone MMTV/c-neu transgenic mice and rodent
carcinogen-induced mammary tumors, indicating that
reduced C/EBPδ expression is relatively common in
mammary epithelial cell tumors regardless of species or
transforming event [16,17]. Mechanistic studies indicate
that hypermethylation and site-specific methylation
within the C/EBPδ proximal promoter is associated with
reduced C/EBPδ gene expression in the human SUM-
52PE breast cancer cell line and in primary human
breast tumors [13]. Silencing of gene expression by epi-
genetic promoter hypermethylation has been previously
reported for a number of tumor suppressor genes
including Rb, p16, p21, BRCA1 and VHL [18]. These
results demonstrate that C/EBPδ shares cancer related
mechanisms of gene silencing with established tumor
suppressor genes.
C/EBPs function as transcriptional regulators in the
differentiation of a variety of cell types, including adipo-
cytes, mammary epithelial cells, myeloid cells, keratino-
cytes and hepatocytes [1,19]. Sequential expression of C/
EBP δ, b and a has been extensively documented in adi-
pocyte differentiation [20]. C/EBPa,C / E B P b knockout
mice and C/EBPb/δ double knockout mice exhibit
reduced in vitro adipocyte differentiation and reduced in
vivo lipid accumulation in adipose tissue [21,22]. C/
EBPδ is also important in differentiation of cells in the
myeloid lineage as ectopic C/EBPδ expression induces
growth arrest and differentiation in chronic myelogen-
ous leukemia cell lines [10]. In contrast, inhibiting C/
EBPδ expression suppresses cytokine-induced granulocy-
tic differentiation of human myeloid leukemia cells [23].
The overall goal of this study was to investigate the
influence of C/EBPδ on growth arrest, migration, inva-
sion and differentiation. Alterations in these fundamen-
tal cell programs are common in cancer cells [24]. The
results demonstrated that reducing C/EBPδ expression
impairs mammary epithelial cell (MEC) growth arrest,
increases MEC migration/invasion and reduces MEC
differentiation. In addition, C/EBPδ knockout MEFs also
exhibited defective growth arrest and increased migra-
tion compared to C/EBPδ wild type MEFs. These results
provide mechanistic insights into the role of C/EBPδ
“loss of function” alterations” in cell transformation and
tumorigenesis.
Results
Reducing C/EBPδ expression by C/EBPδ siRNA treatment
results in defective HC11 mammary epithelial cell growth
arrest
Previous reports from our lab and others have demon-
strated that C/EBPδ gene transcription is highly induced
during G0 growth arrest and C/EBPδ gene expression is
reduced in breast cancer cell lines and primary breast
tumors [7,8,13,15]. To investigate the functional role of
C/EBPδ in mammary epithelial cell G0 growth arrest we
developed stably transfected C/EBPδ siRNA expressing
and vector control HC11 cell lines. Stable C/EBPδ
siRNA expressing HC11 cells exhibited ~90% reduction
in C/EBPδ mRNA and protein levels compared to HC11
parental and vector controls (Figure 1AB). The influence
of C/EBPδ expression HC11 cell growth was investigated
by culturing HC11 cell lines under exponentially grow-
ing or growth arrest conditions. Cell growth (cell prolif-
eration) status was assessed using bromodeoxyuridine
(BrdU) in situ labeling as an indicator of S phase DNA
synthesis. The number of BrdU positive nuclei detected
in all 3 HC11 cell lines cultured under exponentially
growing cell culture conditions was approximately simi-
lar, suggesting that C/EBPδ does not play a major role
under conditions in which cells are actively proliferating
(Figure 1C, left column). The number of BrdU positive
nuclei was dramatically reduced, however, when parental
and vector control HC11 cells were cultured under
growth arrest conditions for 48 hours (Figure 1C, right
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was sustained at relatively elevated levels in the C/EBPδ
siRNA expressing HC11 cells after cultured under
growth arrest conditions for 48 hours (Figure. 1C, right
panel). These results indicate that serum and growth
factor withdrawal activates the growth arrest response in
C/EBPδ expressing HC11 cells, but HC11 cells with
reduced C/EBPδ expression retain the capacity to prolif-
erate in serum and growth factor deficient media.
We next investigated the effect of reduced C/EBPδ
expression on contact mediated growth arrest. To assess
contact mediated growth arrest near (~80%) confluent
HC11 cell lines were cultured in media containing
serum and growth factors (complete growth media,
CGM) for up to 72 hours. [
3H] thymidine incorporation
and BrdU labeling were assessed as indicators of prolif-
eration post confluence. HC11 parental and vector con-
trol cells exhibited a significant decline in [
3H]
thymidine incorporation after 72 hours (Figure 1D). In
contrast, [
3H] thymidine incorporation remained ele-
v a t e da f t e r7 2h o u r sp o s tc o n f l u e n c ei nC / E B P δ siRNA
transfected HC11 cells (Figure 1D). Consistent with the
[
3H] thymidine incorporation data, the BrdU in situ
labeling results also demonstrated that C/EBPδ siRNA
transfected HC11 cells exhibit impaired contact inhibi-
tion (increased BrdU positive nuclei) at 72 hours com-
pared to vector transfected controls (Figure 1E). These
results demonstrate that contact mediated growth arrest
is defective in C/EBPδ siRNA transfected HC11 cells.
We next assessed the association between contact
mediated growth arrest and cellular markers of prolif-
eration and growth arrest. Consistent with previous
reports from our laboratory, C/EBPδ mRNA levels
increase as parental and vector control HC11 cells pro-
gress from sub confluence (0 hr) to full confluence (72
hrs) (Figure 1F) [5,25]. In contrast, C/EBPδ mRNA
Figure 1 Reducing C/EBPδ expression by C/EBPδ siRNA treatment results in defective HC11 mammary epithelial cell growth arrest. (A)
C/EBPδ mRNA levels were assessed in parental (nontransfected) HC11 cells ("-”), empty vector (pSilencer ™ 2.1) transfected HC11 controls
("vector”) and C/EBPδ siRNA transfected ("siRNA”) HC11 cells growth arrested by serum and growth factor withdrawal. Northern blots were
probed with
32P-labelled C/EBPδ and cyclophilin (CP, loading control) cDNA probes. (B) C/EBPδ protein levels were assessed in parental
(nontransfected) HC11 cells (-), empty vector transfected HC11 controls (vector) and C/EBPδ siRNA transfected (siRNA) HC11 cells growth arrested
by serum and growth factor withdrawal. Western blots were probed with primary antibodies against C/EBPδ and b-actin (loading control). (C)
Serum and growth factor withdrawal induced growth arrest assessed by BrdU labeling (brown). HC11 cells were cultured under exponentially
growing (first panel) and 48 hr growth arrested (second panel) conditions. Cells were counterstained with hematoxylin (blue). (D) Contact
inhibition (growth arrest) assessed by [
3H]-thymidine incorporation. HC11 nontransfected control, HC11 vector control and HC11 C/EBPδ siRNA
transfected cells were grown to ~80% confluence (0 hr) in complete growth media (CGM) and then maintained in CGM. [
3H]-thymidine
incorporation (cpm) was assessed at 0, 24 48 and 72 hours. (E) Contact inhibition (growth arrest) assessed by BrdU incorporation (brown). Cells
were treated as described in “D” above. BrdU incorporation was assessed at the designated time points. (F) Contact inhibition (growth arrest)
induction of C/EBPδ mRNA levels. Total RNA was isolated at the designated time points and Northern blots were probed with
32P-labelled C/
EBPδ and cyclophilin (CP, loading control) cDNA probes. (G) Whole cell proteins were isolated at designated time points and Western blots were
probed with primary antibodies against STAT3, pSTAT3, C/EBPδ, cyclin D1 and b-actin (loading control). * = significant different from C/EBPδ
siRNA treated group at 72 hours at p < 0.05.
Yu et al. Cancer Cell International 2010, 10:48
http://www.cancerci.com/content/10/1/48
Page 3 of 11levels are not significantly induced in C/EBPδ siRNA
expressing HC11 cells cultured under the same condi-
tions of confluence (Figure 1F). Previous reports from
our laboratory and others have demonstrated that acti-
vated (phosphorylated) STAT3 (pSTAT3) is the princi-
pal transcriptional activator of C/EBPδ gene expression
in mouse and human cells in response to growth arrest
conditions [25-28]. Reports from our lab and others
have also demonstrated that pSTAT3 levels increase in
growth arrested, nontransformed cells, but alterations in
pSTAT3 levels and pSTAT3 mediated C/EBPδ gene
expression are demonstrable in cancer cell lines
[8,9,13,25,29-32]. Western blot analysis demonstrated
that as parental and vector control HC11 cell lines
approach contact mediated growth inhibition (48-72
hours), pSTAT3 and C/EBPδ protein levels increase and
the levels of Cyclin D1, a marker of cell cycle prolifera-
tion, decline (Figure 1G). In contrast, pSTAT3 and C/
EBPδ protein levels remain relatively low and Cyclin D1
levels remain elevated in C/EBPδ siRNA treated HC11
cells (Figure 1G). Taken together, these results demon-
strate that reducing C/EBPδ expression by siRNA treat-
ment results in defective growth arrest in
nontransformed HC11 mammary epithelial cells.
Reducing C/EBPδ expression increases HC11 cell
migration and invasion
We previously demonstrated by “ChIP-chip” assay that
C/EBPδ activates target genes that function cell adhe-
sion, including integrinb8 (ITGB8), protocadherin 9
(PCDH9) and glycoprotein V (GP5) [33]. We hypothe-
sized that in addition to defective growth control, “loss
of function” alteration in C/EBPδ may also influence cell
migration. HC11 cell migration was assessed using the
in vitro “scratch” assay, an assay that assesses the capa-
city of cells to migrate into an open area created by
“scratching” a confluent cell monolayer [34-36]. The
“scratch’ assay was performed on confluent monolayers
of HC11 cells cultured in complete growth media and
migration into the open area assessed at 0, 24 and 48
hours post-scratch. The results demonstrated that C/
EBPδ siRNA transfected HC11 cells exhibited enhanced
migration into the open area of the cell monolayer com-
pared to parental or vector control cells (Figure 2A). To
determine the influence of exogenous growth factors on
cell migration the scratch assay was performed with
cells cultured at confluence in media lacking serum and
growth factors (Growth arrest media, GAM). Although
overall migration was significantly reduced in all cells
cultured in GAM, the number of cells migrating into
the open area was increased in the C/EBPδ siRNA trans-
fected HC11 cells compared to the parental and vector
control groups (Figure 2B). These results demonstrate
that reducing C/EBPδ expression is associated with
increased cell migration, a property of transformed cells
that is linked to metastasis [35].
To determine if the increased cell migration capability
exhibited by C/EBPδ siRNA treated HC11 cells also
increased cell invasion we performed cell invasion
assays. C/EBPδ siRNA expressing and vector control
HC11 cells were cultured in GAM on extracellular
matrix (ECM) coated inserts and invasion was assessed
by crystal violet staining of cells traversing to the reverse
side of the insert. Although nontransformed HC11 cell
line is minimally invasive in this assay, the results
demonstrated that siRNA mediated reduction of C/EBP
expression increased HC11 cell invasion through the
ECM, indicating that “loss of function” alterations in C/
EBPδ are associated with enhanced cell invasion (Figure
2C).
Reducing C/EBPδ expression inhibits HC11 mammary
epithelial cell differentiation
Early reports associated C/EBPδ expression with adipo-
cyte differentiation and subsequent studies established
that C/EBPδ plays a key regulatory role in adipocyte and
granulocyte differentiation [10,37]. Since C/EBPδ is
involved in the differentiation of cell types of various
lineages we hypothesized that loss of C/EBPδ expression
would alter mammary epithelial cell differentiation.
Figure 2 Reducing C/EBPδ expression increases HC11 cell
migration and invasion. (A) HC11 nontransfected cells, HC11
stably transfected vector (pSilencer ™ 2.1 neo) control ("vector”) cells
and HC11 C/EBPδ siRNA treated cells were grown to confluence in
CGM. A 200 μl pipet tip was used to produce an open area or
“scratch” in the confluent monolayers and migration into the open
area assessed at 0 h, 24 h and 48 h by crystal violet staining. (B)
HC11 cell lines were grown to confluence in CGM and then
switched to growth arrest media (GAM, 0.1% FBS) for 24 hours prior
to the creation of the open area in the cell monolayers. Migration
into the open area in the GAM cultured cells was assessed as
described in “A” above. (C) HC11 vector control and C/EBPδ siRNA
treated cells (1 × 10
6) were suspended in serum-free media and
cultured on the inner (top) chamber of the insert; serum containing
media was placed in the outer (lower) chamber of the insert
(Chemicon Cell Invasion Assay Kit). Plates were incubated for up to
6 days at 37°C. Migration of cells to the lower surface of the
membrane was assessed by staining with crystal violet and
photographed. Results presented are representative of 3
independent experiments with duplicates.
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taining lactogenic hormones and the influence of C/
EBPδ expression on HC11 cell differentiation was
assessed by Northern blot analysis of b-casein mRNA, a
marker of mammary epithelial cell differentiation [17].
The results demonstrated that b-casein mRNA levels
increased in the HC11 parental and vector control cell
lines in response to lactogenic hormone treatment ("+”
columns) compared to control cell lines cultured in the
absence of lactogenic hormones ("-” columns)(Figure 3).
In contrast, lactogenic hormone induction of b-casein
mRNA levels in C/EBPδ siRNA transfected HC11 cells
was minimal, ~20% of that observed in the C/EBPδ
expressing control cell lines (Figure 3). These results
demonstrate that reducing endogenous C/EBPδ levels is
associated with defective HC11 mammary epithelial cell
differentiation.
C/EBPδ knockout (C/EBP -/-) mouse embryo fibroblasts
(MEFs) exhibit defective growth arrest and increased
migration
Primary mouse embryo fibroblasts (MEFs) have been
extensively used as a model system to investigate the
role of specific gene deletions in cell biology [38]. We
hypothesized that C/EBPδ -/- MEFs could serve as a
useful model to investigate the tumor suppressor func-
tions of C/EBPδ. C/EBP +/+ and C/EBP -/- MEFs were
grown to near confluence (0 hr), switched from MCGM
to GAM, and growth arrest induction of C/EBPδ protein
levels assessed. C/EBPδ +/+ MEFs exhibited marked
induction of C/EBPδ protein levels 24 and 48 hours
after exposure to GAM (Figure 4A). In contrast, C/EBPδ
protein levels were undetectable in C/EBPδ -/- MEFs
cultured in GAM, confirming the total abrogation of C/
EBPδ expression in C/EBPδ -/- MEFs (Figure 4A). Next,
we cultured near confluent (~80% confluent) C/EBPδ
+/+ and C/EBPδ -/- MEFs in media deficient in serum
and growth factors (growth arrest media, GAM) and
assessed the growth arrest response using [
3H] thymi-
dine incorporation and BrdU labeling as S phase (prolif-
eration) indicators. The results demonstrated that C/
EBPδ +/+ MEFs exhibited a rapid, time dependent
(within 24 hrs) decline in [
3H] thymidine incorporation
following exposure to GAM (Figure 4B). This decline in
[
3H] thymidine incorporation persisted in the C/EBPδ
+/+ MEFs at the 48 hr time point (Figure 4B). In con-
trast, [
3H] thymidine incorporation remained elevated in
the C/EBPδ -/- MEFs after prolonged (48 hours) of cul-
ture in GAM (Figure 4B). Similarly, BrdU labeling
declined in C/EBPδ +/+ MEFs after 24 and 48 hours of
culture in GAM (Figure 4C). BrdU labeling remained
elevated in C/EBPδ -/- MEFs after 24 and 48 hours of
culture in GAM (Figure 4C). To further investigate the
role of C/EBPδ in contact-mediated growth arrest C/
EBPδ -/- MEFs were transfected with an empty expres-
sion plasmid (pcDNA3) or a C/EBPδ expression plasmid
and cultured in MEF Complete Growth Media
(MCGM). C/EBPδ -/- MEFs receiving the C/EBPδ
expression plasmid exhibited decreased [
3H] thymidine
incorporation, consistent with growth inhibition (Figure
4D). In contrast, [
3H] thymidine incorporation contin-
ued to increase in C/EBPδ -/- MEFs transfected with
the empty pcDNA3 control vector (Figure 4D). These
results demonstrate that C/EBPδ plays a key role in acti-
vating growth arrest in MEFs. We next investigated the
influence of C/EBPδ on MEF migration using the in
vitro scratch assay. The results demonstrated that a uni-
form open area was created on the C/EBPδ -/- and C/
EBPδ -/- MEF cell monolayers at t = 0 (Figure 4E).
After 24 hours, however, the C/EBPδ -/- MEFs
Figure 3 Reducing C/EBPδ expression inhibits HC11 mammary epithelial cell differentiation. HC11 nontransfected control cells, HC11
stably transfected vector (pSilencer™ 2.1 neo) control ("vector”) cells and HC11 C/EBPδ siRNA treated cells were grown to confluence in CGM.
Cells were cultured in CGM without lactogenic hormones (-) or in CGM plus lactogenic hormones (+) for 4 days. Total cellular RNA was isolated
and Northern blot analysis performed. Northern blots were probed with
32P-labelled C/EBPδ and b-casein expression cDNA probes. CP was used
as the loading control. Results presented are for mRNA levels from duplicate samples analyzed in this experiment. The results presented are
representative of 3 experiments.
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open area compared to C/EBPδ +/+ MEFs (Figure 4E).
These results are consistent with the results presented
in Figure 2 and further demonstrate that “loss of func-
tion” alterations in C/EBPδ enhance cell migration.
C/EBPδ DNA binding and bZIP domains function in the
suppression of HC11 cell colony growth
C/EBPs are organized in a domain structure composed
of an N terminal transactivation domain, regulatory
domain and highly conserved C-terminal basic region
(BR) and leucine zipper (bZIP) domains [2]. CEBPs
function primarily as DNA binding transcriptional acti-
vators [1,2]. To determine if the C/EBPδ transcriptional
activation function plays a role in colony growth HC11
cells were transfected with C/EBPδ full length and C/
EBPδ bZIP and C/EBPδ BR + bZIP deletion constructs
and colony growth (clonogenic) assays performed. The
results demonstrated that the C/EBPδ full length con-
struct suppressed HC11 cell colony growth compared to
the transcriptional activation defective C/EBPδ bZIP and
C/EBPδ BR + bZIP deletion constructs (Figure 5). These
findings demonstrate that the C/EBPδ domains that
mediate transcriptional activation (i.e., BR and bZIP)
play a major role in C/EBPδ mediated suppression of
HC11 cell colony growth.
Discussion
These findings provide mechanistic insights into the role
of C/EBPδ as a tumor suppressor gene and support
experimental and clinical reports that have linked “loss
of function” alterations in C/EBPδ with aberrant cell
growth and tumorigenesis [6,8-11,13-15,39]. Early
reports demonstrated that C/EBPδ functioned as a tran-
scriptional activator in growth arrest and differentiation
of pre-adipocyte and acute phase responding cells
[37,40]. The results from this study extend these results
to nontransformed mammary epithelial cells and pri-
mary embryo-derived fibroblasts, demonstrating that C/
EBPδ regulates cell fate determining programs in a
broad range of cell types. Recent studies indicate that C/
EBPδ gene expression is induced in hormone responsive
breast and prostate cancer cells, but C/EBPδ induction
and growth arrest is lost in more advanced, hormone
unresponsive breast and prostate cancer cells [39]. In
addition to breast and prostate, the association between
C/EBPδ, growth control and differentiation extends to
myeloid lineage cells. C/EBPδ expression is silenced by
Figure 4 C/EBPδ knockout (C/EBP -/-) mouse embryo fibroblasts (MEFs) exhibit defective growth arrest and increased migration. (A) C/
EBPδ protein levels in C/EBPδ +/+ and C/EBPδ -/- MEFs. C/EBPδ +/+ and C/EBPδ -/- MEFs were cultured in MCGM to ~80% confluence and then
switched to GAM. Whole cell lysates were isolated and western blots performed at 0 (near confluence), 24 and 48 hrs. Western blots were
probed with anti- C/EBPδ and b-actin antibodies. (B) [
3H]-thymidine incorporation. C/EBPδ +/+ and C/EBPδ -/- MEFs were treated as described in
“A” above. [
3H]-thymidine incorporation assessed at 0, 24 and 48 hrs. * = significantly different from C/EBPδ +/+ treatment group at 24 and 48
hours at p < 0.05. (C) BrdU labeling. C/EBPδ +/+ and C/EBPδ -/- MEFs were treated as described in “A” and BrdU labeling detected by in situ
immunocytochemisty. (D) C/EBPδ Rescue. C/EBPδ -/- MEFs were transfected with pcDNA3 (empty vector control) or with full length C/EBPδ
cloned into pcDNA3. Confluent cells were cultured in MCGM and [
3H]-thymidine incorporation assessed at 0, 24 and 48 hrs post-confluence. The
values presented are mean ± S.E.M from three independent experiments. * = significantly different from MEFs transfected with C/EBPδ
expression vector at 24 and 48 hours at p < 0.05. Migration assay. C/EBPδ +/+ and C/EBPδ -/- MEF confluent monolayers cultured in MCGM
were “scratched” with a 200 μL pipet tip as described in the Methods section. Migration of cells into the open area was assessed at 0 and 24 hrs
by crystal violet staining.
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(AML) patient samples and C/EBPδ is significantly
reduced in minimally differentiated, poor prognosis,
AML:M0 patient samples [11,41]. Taken together, these
results indicate that C/EBPδ “loss of function” altera-
tions are associated with a wide range of “solid” tumors
and in leukemia.
In this report we show that reducing C/EBPδ expres-
sion by siRNA and gene knockout increased cell migra-
tion and invasion, consistent with a role for “loss of
function” alterations in C/EBPδ in advanced cancer pro-
gression and metastasis. Importantly, these experiments
demonstrate that reducing C/EBPδ expression levels
increased cell migration under growth arrest conditions,
a condition in which C/EBPδ expression is elevated and
cell migration is dramatically inhibited (Figure 2B).
These findings extend basic studies in which Slow bor-
der cells (slbo), a Drosophila basic region/leucine zipper
(C/EBP) homologue, was shown to function as a regula-
tor of border cell cluster formation, adhesion and migra-
tion in the Drosophila ovary [35]. Border cell cluster
formation is a complex biological phenomenon that
requires activation of adhesion and migration programs.
Using “ChIP-chip” assays we previously identified C/
EBPδ target genes that function in cell adhesion, includ-
ing glycoprotein V (GP5), protocadherin 9 (PCDH9) and
integrin b8 (ITGB8) [33]. The present results indicate
that reducing C/EBPδ expression plays a potentially
important role in promoting cell migration, a critical
pathogenic event in metastasis.
C/EBPδ domain deletion experiments demonstrated
that the transcriptional activator function of C/EBPδ is
required for the suppression of HC11 cell colony
growth. Colony growth suppression could result from
C/EBPδ induced growth arrest or increased apoptosis
[6]. We previously identified C/EBPδ target genes with
functional roles in cell cycle regulation and apoptosis
including septin 7 (SEPT7), regulator of chromosome
condensation I (RCCI), DIRAS family GTP-binding Ras-
like 3 (DIRAS3) and BCL1-like 1 (BCL2L1) [33]. Tran-
scriptional activation of these C/EBPδ target genes, or
indirect activation of C/EBPδ associated gene networks
could induce colony growth inhibition [42]. Current stu-
dies are investigating the regulation and function of
selected C/EBPδ target genes in the control of cell
growth, differentiation and migration/invasion.
Conclusion
An important goal in basic cancer research is to identify
biological alterations that promote tumor development
and progression and to use this information to design
interventions strategies to prevent or treat cancer. The
results of this study provide new insights into the func-
tion of C/EBPδ in cell biology using a nontransformed
mammary epithelial cell line and primary embryo fibro-
blasts. The results provide new insights into the role of
Figure 5 C/EBPδ transcriptional activator function is required for suppression of HC11 mammary epithelial cell colony growth. HC11
cells were transfected with expression constructs encoding C/EBPδ cDNA full length (FL), C/EBPδ bZIP domain deleted (DB) or C/EBPδ bZIP +
DNA binding domain deleted (TA) constructs. HC11 cells transfected with the pcDNA3 vector alone yielded ~1,000 colonies (positive control).
For all clonogenic assays, cells were cultured for 15 days in Complete Growth Media (CGM) plus G418. Surviving colonies were stained with a
0.5% crystal violet/20% methanol solution and counted. * = significantly different from HC11 cells transfected with the full length (FL) C/EBPδ
expression vector at p < 0.05.
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differentiation and migration. These findings suggest
that intervention strategies that increase the expression,
activation or function of C/EBPδ could have a positive
impact or reducing the incidence or impeding the pro-
gression of cancer.
Methods
Cell culture
The nontransformed HC11 mouse mammary epithelial
cell line used in these studies was obtained as a gener-
ous gift from Dr. Wolfgang Doppler (University of
Innsbruck). HC11 cells were cultured in complete
growth media (CGM) containing RPMI 1640 medium
supplemented with 5% fetal bovine serum (FBS), 10 μg/
ml bovine insulin, 10 ng/ml epidermal growth factor,
100 U/ml penicillin, 100 μg/ml streptomycin and 500
ng/ml Fungizone. To induce growth arrest by serum
and growth factor withdrawal, HC11 cells were cultured
to ~80% confluence in CGM and then witched to media
deficient in serum and growth factors (growth arrest
medium, GAM, 0.1% FBS). To induce growth arrest by
contact inhibition, cells were grown to ~80% confluence
and maintained in CGM for up to 72 hrs.
Mouse embryo fibroblasts (MEFs) were prepared by
harvesting 13.5 day old littermate embryos derived from
mating of C/EBPδ +/- heterozygous mice of the C57BL/
6 inbred strain. After removing the internal organs and
forelimbs, embryos were minced with sterile scissors
and incubated with 1 ml of 0.25% (w/v) Trypsin/EDTA
solution at 4°C for 6 hours. After incubation, the fibro-
blast enriched cell preparations were rinsed and cultured
in MEF complete growth media (MCGM) composed of
DMEM supplemented with 10% (v/v) FBS, 0.2% (v/v)
0.1 M 2-Mercaptoethanol, 1% (w/v) L-Glutamine and
1% (w/v) Penicillin/Streptomycin. MEFS were cultured
in MCGM until crisis. Post-crises MEF colonies were
isolated and cell lines were established and genotyped as
C/EBPδ +/+ or -/-. For growth arrest experiments,
MEFS were cultured in media composed of DMEM plus
0.5% FBS plus antibiotics. To induce growth arrest by
contact inhibition, MEFs were grown to ~80% conflu-
ence and maintained in MCGM for up to 72 hrs. All
cultured cells tested negative for the presence of myco-
plasma using the Lonza MycoAlert Mycoplasma Detec-
tion Kit Cat#: LT07-118 and MycoAlert Assay Control
set Cat #: LT07-518.
C/EBPδ siRNA interference
C/EBPδ RNA interference was induced with short inter-
fering RNA (siRNA) directed against the mouse single
exon C/EBPδ gene as previously described [43]. C/EBPδ
specific complementary 65 mer oligonucleotides with
5’overhangs were annealed and ligated into pSilencer
2.1-U6 neo SiRNA expression vectors (Applied Biosys-
tems/Ambion). “Scrambled” siRNAs were purchased
from Dharmacon (Thermo Scientific). Scrambled siR-
NAs are nontargeting siRNAs based on genome Blast
and microarray analysis performed by Dharmacon.
Sequence verified siRNA constructs were transfected
into HC11 cells using Lipofectamine (Invitrogen). Stable
HC11 cell transfectants were selected by culturing in
the presence of with 400 μg/ml G418 for ~15 days. Fol-
lowing selection, stable HC11 cells were maintained in
200 μg/ml G418. C/EBPδ expression levels were assayed
by Northern and Western blots. HC11 cells with
reduced C/EBPδ expression (>80%) were used for
further study.
Northern blot analysis
Total cellular RNA was isolated from cultured cells
using RNA-Bee (Tel-Test, Inc.). Cells were rinsed with
PBS and 3.5 ml RNA-Bee was used per 100 mm plate.
RNA was precipitated with isopropanol, washed with ice
cold 75% ethanol and the RNA pellet dissolved in DEPC
water. Total RNA (20 μg) was loaded onto a 1.2% agar-
ose gel and electrophoresed for 2 hr at 150 V. RNA was
transferred to Duralon UV membrane (Stratagene), UV
cross linked, pre-hybridized and probed with [a-
32P]
dCTP random primer labeled C/EBPδ, b-casein and
cyclophilin (CP) cDNAs probes. Hybridization was per-
formed overnight at 42°C. CP was used as a loading
control. Results were analyzed from densitometric mea-
surements taken by AlphaImager 2000 (Alpha Innotech).
Results are representative of 3 independent experiments.
Western blot analysis
Western blots were performed as previously described
[44]. Cells were rinsed with ice cold PBS, scraped from
the plastic plate with a rubber policeman, and lysed in
protease containing buffer for 30 mins at 4°C. Total cell
lysates were isolated by centrifugation and the soluble
supernatant was collected and protein levels quantified
by BCA microprotein assay kit (Pierce). Protein lysates
(40 μg) were resolved by sodium dodecyl sulfate-polya-
crylamide gel electrophoresis (SDS-PAGE), transferred
to Immobilon-P PVDF membrane (Millipore), and
membranes were blocked for 1 hr with PBS containing
10% non-fat dry milk and 0.5% Tween 20. Membranes
were incubated with PBST containing 5% non-fat dry
milk and primary antibodies against C/EBPδ (1:1000,
rabbit, Santa Cruz), cyclin D1 (1:2500, mouse, Cell Sig-
naling), pSTAT3 (Tyr705) (1:2500, rabbit, Cell Signal-
ing), STAT3 (1:3000, rabbit, Cell Signaling) or b-actin
(1:2000, rabbit, Cell Signaling). After washing with PBS,
membranes were probed with horseradish peroxidase
(HRP)-conjugated anti-rabbit or anti-mouse secondary
antibody (1:3000, Cell Signaling) for 1 hr. Membranes
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luminescence detection reagent (Amersham Pharmacia).
Results are representative of 3 independent experiments.
[
3H]-thymidine incorporation assay
The [
3H]-thymidine incorporation assay was performed
as previously described [8]. HC11 cells were seeded in
12-well plates at 9 × 10
4 cell/ml in 1 ml CGM and
grown to confluence. At the designated time points (0
h, 24 h, 48 h and 72 h), 1 μCi/ml [methyl-
3H]-thymidine
cells was added to the culture media for 2 hr. Cell cul-
ture dishes were rinsed twice with PBS, precipitated
with ice cold 10% trichloroacetic acid (TCA) for 10 min
at 4°C, and solubilized in 0.3N NaOH containing 1%
SDS. Incorporation of [methyl-
3H]-thymidine into TCA
precipitated DNA was measured by liquid scintillation
counting. Results represent the average of 2 independent
experiments with 3 wells/time point.
Bromodeoxyuridine (BrdU) In Situ assay
Cells were plated on 2-well chamber slides at ~9 × 10
4/
ml, grown to near-confluence in CGM and maintained
in CGM or GAM. The BrdU incorporation assay was
performed using BrdU In Situ detection kit (BD Phar-
mingen). Briefly, 5-bromo-2-deoxyuridine was added to
cells with a final concentration of 10 μM/L at the indi-
cated time points and incubated for 2 hrs. Cells were
fixed with ice cold methanol at -20°C for 20 min and
endogenous peroxidase activity was blocked by incubat-
ing slides in 0.3% H2O2 for 10 min. After heat antigen
retrieval, slides were immunostained with biotinylated
anti-BrdU antibody and detected by streptavidin-HRP
and 3,3’-diaminobenzidine tetrahydrochloride (DAB).
Cells were counterstained with hematoxylin for 40 sec-
onds (Vector Lab), cleared with xylene and coverslipped.
Migration “scratch” assay
HC11 cell migration was assessed by the in vitro
“scratch” assay as previously described [34,43]. Cells
were plated on 100 mm tissue culture plates and grown
to confluence. An open area or “scratch” was produced
in the HC11 cell monolayer using a 200 μl micropipette
tip. HC11 Cells were washed with PBS to remove the
displaced cells in the open area, and cultured in CGM
or GAM for designated times. MEFs were similarly trea-
ted and cultured in MCGM. Migration into the open
area was assessed by staining parallel dishes with 0.5%
crystal violet in 20% methanol for 3 minutes.
Cell invasion Assay
Cell invasion assays were performed using the Chemi-
con Cell Invasion Assay Kit (Chemicon Int.). 1 × 10
6
cells were suspended in serum-free media and cultured
on the inner (top) chamber of the insert; media with
serum was placed in the outer (lower) chamber of the
insert. Plates were incubated for up to 6 days at 37°C.
Invasive cells which had migrated to the lower surface
of the membrane were stained with crystal violet and
photographed. Results presented are representative of 3
independent experiments with duplicates.
HC11 cell differentiation Assay
HC11 cell differentiation assay was performed as pre-
viously described [17]. HC11 cells were seeded on 100
mm culture plates and grown to confluence. Confluent
cells were washed with PBS twice and maintained in
epidermal growth factor (EGF) free RPMI 1640 medium
supplemented with 2% FBS, 5 μg/ml insulin, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 500 ng/ml fun-
gizone for two days. To induce differentiation 5 μg/ml
prolactin (Sigma) and 0.1 μM dexamethasone (Sigma)
were added to the medium and cells were cultured for
an additional four days. HC11 cells not treated with
prolactin and dexamethasone were used as control.
RNA and protein samples were isolated as described
above.
Clonogenic Assay
The clonogenic assay was performed as previously
described [8]. HC11 cells were transfected with 1 μgo f
the following constructs cloned into the pcDNA3
expression vector: C/EBPδ cDNA full length (FL), C/
EBPδ bZIP domain deleted (DB) or C/EBPδ bZIP +
DNA binding domain deleted (TA) constructs. Transfec-
tions were performed using Lipofectamine Plus (Invitro-
gen) and following transfections cells were cultured in
complete growth media plus 400 μg/mL G418 (Geneti-
cin). Colonies were stained with a 0.5% crystal violet/
20% methanol solution.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism
statistical software. Statistical analysis of treatment
group means at multiple time points was performed by
one-way analysis of variance (ANOVA). Posttest multi-
ple comparisons of groups means was performed using
Tukey’s test.
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